Deutetrabenazine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Deutetrabenazine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
21
Registered trials
44
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Deutetrabenazine can convert its Small molecule drug profile and VMAT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Deutetrabenazine (query alias: Deutetrabenazine) |
|---|---|
| Modality / target | Small molecule drug; VMAT2; VMAT2 inhibitors |
| Highest global status | Approved |
| Originator | Teva Pharmaceutical Industries Ltd. |
| Active developers | Teva GmbH, Teva Branded Pharmaceutical Products R&D LLC, Teva Pharmaceuticals Australia Pty Ltd |
The MCP disease footprint includes Chorea, Tardive Dyskinesia, Huntington Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07601516 | Phase 4 | Completed | 50 | Change in Total Maximal Chorea (TMC) Score in participants receiving ≥24 mg/day |
| NCT06997198 | Phase 4 | Recruiting | 25 | Change in AIMS total scores of items 1-7 |
| ChiCTR2300076925 | Phase 1 | Recruiting | 20 | Pharmacokinetic |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Real-World Effectiveness of the 4-Week Patient Deutetrabenazine-Titration Kit for Tardive Dyskinesia Across Races: START Study Post Hoc Analysis
Not Applicable; n=53; evaluation: Positive. Reported fields: -; AE = 11.0 Pts
Efficacy and Safety of Deutetrabenazine in Huntington’s Disease: a Systematic Review
Not Applicable; n=154; evaluation: Positive. Reported fields: AE = AEs including falls (38% RC, 43% SC), depression (32%, 22%), anxiety (27%, 35%), insomnia (23%, 16%), somnolence (20%, 30%), and akathisia (6%, 11%). Less frequent AEs included suicidality (9%, 5%) and parkinsonism (4%, 8%) (Frank et al., 2022). ; AE = AEs including falls (38% RC, 43% SC), depression (32%, 22%), anxiety (27%, 35%), insomnia (23%, 16%), somnolence (20%, 30%), and akathisia (6%, 11%). Less frequent AEs included suicidality (9%, 5%) and parkinsonism (4%, 8%) (Frank et al., 2022).
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: -; CGIC = 65 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Deutetrabenazine addresses Chorea, Tardive Dyskinesia, Huntington Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-02-26 | 恩华药业与梯瓦达成战略合作 获安泰坦中国大陆独家商业化权益 | Approved | Financial terms not disclosed |
| 2020-07-21 | 梯瓦上药携手战略合作，共同呵护“安稳人生” | Approved | Financial terms not disclosed |
| 2015-03-30 | Teva Completes Acquisition of Auspex Pharmaceuticals | Approved | US$3,200.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Osmotic dosage forms comprising deutetrabenazine and methods of use thereof”. The milestone feed surfaced a patent-application signal described as “Multiparticulate dosage forms comprising deutetrabenazine”. The milestone feed surfaced a patent-application signal described as “Osmotic dosage forms comprising deutetrabenazine and methods of use thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
